Gene · 2175
Papers3,803
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
781 to 800 of 3,803
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Senescence plays a role in myotonic dystrophy type 1. | JCI Insight | 2022 | 36040809 | PubTator, text mining | PubMed |
| Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice. | Clin Cancer Res | 2022 | 36040493 | PubTator, text mining | PubMed |
| Wnt/β-Catenin-Pathway Alterations and Homologous Recombination Deficiency in Cholangiocarcinoma Cell Lines and Clinical Samples: Towards Specific Vulnerabilities. | J Pers Med | 2022 | 36013219 | PubTator, text mining | PubMed |
| Reducing the Effectiveness of Ward Particulate Matter, Bacteria and Influenza Virus by Combining Two Complementary Air Purifiers. | Int J Environ Res Public Health | 2022 | 36012090 | PubTator, text mining | PubMed |
| How Can Apartment-Complex Landscaping Space Improve Residents' Psychological Well-Being?: The Case of the Capital Region in South Korea. | Int J Environ Res Public Health | 2022 | 36011865 | PubTator, text mining | PubMed |
| BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. | Cancers (Basel) | 2022 | 36010882 | PubTator, text mining | PubMed |
| Molecular Threat of Splicing Factor Mutations to Myeloid Malignancies and Potential Therapeutic Modulations. | Biomedicines | 2022 | 36009519 | PubTator, text mining | PubMed |
| Redefining germline predisposition in children with molecularly characterized ependymoma: a population-based 20-year cohort. | Acta Neuropathol Commun | 2022 | 36008825 | PubTator, text mining | PubMed |
| Diversity of Phospholipases A2 from Bothrops atrox Snake Venom: Adaptive Advantages for Snakes Compromising Treatments for Snakebite Patients. | Toxins (Basel) | 2022 | 36006204 | PubTator, text mining | PubMed |
| Editorial: Molecular influences in therapies in ovarian cancer. | Front Oncol | 2022 | 36003794 | PubTator, text mining | PubMed |
| Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer-A Review of Molecular Characterisation, Therapeutic Targets and Future Trends. | Front Oncol | 2022 | 36003779 | PubTator, text mining | PubMed |
Proteomics-based evaluation of the mechanism underlying vascular injury via DNA interstrand crosslinks, glutathione perturbation, mitogen-activated protein kinase, and Wnt and ErbB signaling pathways induced by crotonaldehyde. | Clin Proteomics | 2022 | 36002804 | PubTator, text mining | PubMed |
| The potential effects and mechanisms of breast inflammatory lesions on the occurrence and development of breast cancer. | Front Oncol | 2022 | 35992864 | PubTator, text mining | PubMed |
| Comprehensive analyses unveil novel genomic and immunological characteristics of micropapillary pattern in lung adenocarcinoma. | Front Oncol | 2022 | 35992814 | PubTator, text mining | PubMed |
| Novel MEIOB variants cause primary ovarian insufficiency and non-obstructive azoospermia. | Front Genet | 2022 | 35991565 | PubTator, text mining | PubMed |
| Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients. | Pathol Res Pract | 2022 | 35988354 | PubTator, text mining | PubMed |
| Integrase deficient lentiviral vector: prospects for safe clinical applications. | PeerJ | 2022 | 35979475 | PubTator, text mining | PubMed |
| Chromosomal instability in adult-type diffuse gliomas. | Acta Neuropathol Commun | 2022 | 35978439 | PubTator, text mining | PubMed |
| Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. | J Immunother Cancer | 2022 | 35977756 | PubTator, text mining | PubMed |
| Breaking the aging epigenetic barrier. | Front Cell Dev Biol | 2022 | 35966762 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2175/papers?page=40